- Home
- KIND vs KURA Comparison
KIND vs KURA Comparison
Compare KIND & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- KURA
- Stock Information
- Founded
- KIND 2011
- KURA 2014
- Country
- KIND United States
- KURA United States
- Employees
- KIND N/A
- KURA N/A
- Industry
- KIND Computer Software: Programming Data Processing
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KIND Technology
- KURA Health Care
- Exchange
- KIND Nasdaq
- KURA Nasdaq
- Market Cap
- KIND 608.3M
- KURA 492.9M
- IPO Year
- KIND N/A
- KURA N/A
- Fundamental
- Price
- KIND $1.53
- KURA $5.85
- Analyst Decision
- KIND Buy
- KURA Strong Buy
- Analyst Count
- KIND 3
- KURA 12
- Target Price
- KIND $2.75
- KURA $24.50
- AVG Volume (30 Days)
- KIND 1.8M
- KURA 1.2M
- Earning Date
- KIND 08-06-2025
- KURA 08-07-2025
- Dividend Yield
- KIND N/A
- KURA N/A
- EPS Growth
- KIND N/A
- KURA N/A
- EPS
- KIND N/A
- KURA N/A
- Revenue
- KIND $248,306,000.00
- KURA $67,991,000.00
- Revenue This Year
- KIND $1.77
- KURA $109.86
- Revenue Next Year
- KIND $10.72
- KURA $107.90
- P/E Ratio
- KIND N/A
- KURA N/A
- Revenue Growth
- KIND 12.01
- KURA N/A
- 52 Week Low
- KIND $1.32
- KURA $5.41
- 52 Week High
- KIND $3.00
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- KIND 47.53
- KURA 40.44
- Support Level
- KIND $1.51
- KURA $5.56
- Resistance Level
- KIND $1.69
- KURA $7.17
- Average True Range (ATR)
- KIND 0.07
- KURA 0.38
- MACD
- KIND -0.00
- KURA -0.06
- Stochastic Oscillator
- KIND 11.11
- KURA 6.05
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services. It offers a comprehensive suite of advertising solutions designed to deliver exceptional value for businesses of all size.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.